Validation of a treatment satisfaction questionnaire in patients with moderate to severe psoriasis.: Neoderma study

被引:0
|
作者
Dauden, E. [1 ]
Hernanz, J. M. [2 ]
Puig, Ll. [3 ]
Ribera, M. [4 ]
Garcia-Patos, V. [5 ]
Bordas, X. [6 ]
Vanaclocha, F. [7 ]
机构
[1] Hosp La Princesa, Madrid, Spain
[2] Hosp Gregorio Maranon, Madrid, Spain
[3] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[4] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[5] Hosp Valle De Hebron, Barcelona, Spain
[6] Hosp Bellvitge Princeps Espanya, Barcelona, Spain
[7] Hosp 12 Octubre, Madrid, Spain
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
An observational, prospective, multicenter study, with 423 moderate to severe psoriasis patients, was conducted to validate a new Psoriasis Treatment Satisfaction Questionnaire. Feasibility: 98.9% of patients completed the whole questionnaire. Factor analysis revealed a unique dimension that explained 54.6% of total variance (cross-sectional validity). The questionnaire score presented low-moderate correlations with PASI index along the study (r=0.15 to 0.38) and high correlations with patient's global assessment of treatment satisfaction (r=-0.75 to -0.81) (longitudinal validity). Good internal reliability (global Cronbach's alpha of 0.92) and reproducibility (intraclass correlation coefficient of 0.89) were also demonstrated. The new questionnaire for the assessment of treatment satisfaction in psoriasis is a useful, feasible and reliable tool.
引用
收藏
页码:805 / +
页数:2
相关论文
共 50 条
  • [41] What are the objectives of moderate to severe psoriasis treatment?
    Ortonne, J. -P.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2008, 135 : S281 - S284
  • [42] The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
    Gupta, Rishu
    Debbaneh, Maya
    Butler, Daniel
    Huynh, Monica
    Levin, Ethan
    Leon, Argentina
    Koo, John
    Liao, Wilson
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2013, (77):
  • [43] Tofacitinib for the treatment of moderate-to-severe psoriasis
    Chiricozzi, Andrea
    Faleri, Sara
    Saraceno, Rosita
    Bianchi, Luca
    Buonomo, Oreste
    Chimenti, Sergio
    Chimenti, Maria Sole
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (04) : 443 - 455
  • [44] Efalizumab for the treatment of moderate to severe plaque psoriasis
    Jordan, JK
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (09) : 1476 - 1482
  • [45] The use of methotrexate in treatment of moderate to severe psoriasis
    Leung, W. Y.
    Lau, K. H.
    HONG KONG JOURNAL OF DERMATOLOGY & VENEREOLOGY, 2009, 17 (01): : 13 - 19
  • [46] Update on risankizumab for the treatment of moderate to severe psoriasis
    Al-Janabi, A.
    Warren, R. B.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (11) : 1245 - 1251
  • [47] Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis
    Li, Wendy
    Ghamrawi, Rima
    Haidari, Wasim
    Feldman, Steven R.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (04) : 380 - 387
  • [48] Treatment of moderate-to-severe plaque psoriasis
    Salgo, R.
    Thaci, D.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (06): : 701 - 711
  • [49] VALIDATION STUDY OF AN EMOLLIENT SATISFACTION QUESTIONNAIRE
    Rowley, Georgia
    MacNeill, Stephanie
    Ridd, Matthew
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 35 - 35
  • [50] Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis
    Augustin, Matthias
    Mrowietz, Ulrich
    Willsmann-Theis, Dagmar
    Gerdes, Sascha
    Fotiou, Konstantinos
    Schuster, Christopher
    Mert, Can
    Holzkaemper, Thorsten
    Behrens, Frank
    Pinter, Andreas
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024,